Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch Amsparity (adalimumab) in the EU, citing unfavourable market conditions.
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.